Tina Nova
InvestorPhD; supports the Tullis investment process at Tullis Health Investors
Find your path to Tina
14 people in our graph share verified history with Tina — schools, employers, funds. One of them is your warm intro.
About
Tina Nova is a molecular diagnostics entrepreneur and inventor on numerous scientific patents who supports Tullis Health Investors across deal sourcing, due diligence, and investment management. She co-founded Genoptix, took it public, and sold it to Novartis in 2011, and later led Decipher Biosciences, which was acquired by Veracyte in 2021. She has also held leadership roles at Molecular Stethoscope, Illumina's oncology unit, and Nanogen, which she co-founded. She holds a BS in biological sciences from UC Irvine and a doctorate in biochemistry from UC Riverside.
Invests in
BiotechDigital HealthMedical Devices
Deals · 1
FirstString ResearchBoard seat
via Tullis Health Investors · filed Jun 2021 · $30M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Azenta, Inc.Exagen, Inc.
Sources: the firm's website · SEC Form D filings.
Colleagues at Tullis Health Investors
Frequently asked questions
- Who is Tina Nova?
- Tina Nova is a molecular diagnostics entrepreneur and inventor on numerous scientific patents who supports Tullis Health Investors across deal sourcing, due diligence, and investment management. She co-founded Genoptix, took it public, and sold it to Novartis in 2011, and later led Decipher Biosciences, which was acquired by Veracyte in 2021. She has also held leadership roles at Molecular Stethoscope, Illumina's oncology unit, and Nanogen, which she co-founded. She holds a BS in biological sciences from UC Irvine and a doctorate in biochemistry from UC Riverside.
- Where does Tina Nova work?
- Tina Nova is PhD; supports the Tullis investment process at Tullis Health Investors.
- What does Tina Nova invest in?
- Tina Nova invests in Biotech, Digital Health, Medical Devices.
- What boards does Tina Nova sit on?
- Tina Nova holds tracked board seats at Azenta, Inc., Exagen, Inc., FirstString Research.